NY-ALVAREZ-&-MARSAL
11.1.2024 16:01:30 CET | Business Wire | Press release
Leading global professional services firm Alvarez & Marsal (A&M) has announced the promotion of 69 professionals, across Europe and Middle East, India, Latin America, North America, North Asia and Southeast Asia & Australia to the position of Managing Director.
Tony Alvarez II and Bryan Marsal, A&M’s Co-Founders, stated, “Congratulations to all our newly promoted Managing Directors. Their contributions to our core values of integrity, quality, objectivity, fun, personal reward and inclusive diversity are what make A&M unique. Their commitment to help clients maximize value and drive change amidst ongoing macro-economic challenges builds upon our legacy of operational excellence while advancing our results-oriented mission. They, alongside all A&M professionals, are our greatest strength.”
2024 MANAGING DIRECTOR PROMOTIONS
Europe and Middle East
- Cristiano Battelli, Private Equity Performance Improvement -- Milan
- Paul Culham, Global Transaction Advisory Group -- London
- Louis Darrieus, Global Transaction Advisory Group -- Paris
- Steve Green, Debt Advisory -- London
- Josefine Haensel, Corporate Transformation Services -- Hamburg
- Samih Hajar, Global Transaction Advisory Group -- Paris
- Cheng He, Global Transaction Advisory Group -- London
- Michal Kapela, Global Transaction Advisory Group -- Zurich
- Zeeshan Mansoor, Financial Services Industry -- Amsterdam
- Michael Nizet, Financial & Operational Restructuring -- Amsterdam
- Robert Park, Corporate Transformation Services -- London
- Tom Paterson, Debt Advisory -- London
- Adam Paxton, Insolvency -- London
- Felix Schweigger, Private Equity Performance Improvement -- Munich
- Steve Smith, Tax -- London
- Sebastien Trochet, Digital & Technology Services -- Paris
- Yann Varin, Private Equity Performance Improvement -- Paris
- Nick Walton, Tax -- Manchester
India
- Ashish Doshi, Global Transaction Advisory Group -- Mumbai
- Ram Panda, Business Transformation Services -- Mumbai
Latin America
- Guilherme Almeida, Corporate Transformation -- São Paulo
- Luiz Gronau, Infrastructure & Capital Projects (A&M INFRA) -- São Paulo
- Eduardo Magalhaes, Global Disputes and Investigations -- São Paulo
North America
- Richard Behrens, North American Commercial Restructuring -- Los Angeles
- Brett Bergamo, Energy -- Houston
- Amy Best, Global Disputes and Investigations -- Denver
- Matthew Box, Healthcare -- Washington, D.C.
- Aaron Busse, Corporate Performance Improvement -- Atlanta
- Meghan Cardell, Global Disputes and Investigations -- Washington, D.C.
- Evan Colwell, Global Transaction Advisory Group -- Nashville
- Steve Coverick, North American Commercial Restructuring -- Dallas
- Jorge de Los Reyes, Infrastructure & Capital Projects (A&M INFRA) -- Washington, D.C.
- Beata De Zagon, Global Transaction Advisory Group -- Dallas
- Alex Duff, Private Equity Performance Improvement -- New York
- Ryan Duffy, Global Transaction Advisory Group -- Chicago
- Kyle Foust, Tax -- Chicago
- Max Fulton, Private Equity Performance Improvement -- Denver
- Jen Fults, Tax -- New York
- Jeffrey Gerarde, Tax -- Washington, D.C.
- John Hanson, North American Commercial Restructuring -- Dallas
- Sam Jones, Global Transaction Advisory Group -- Chicago
- Andrew Khoo, North American Commercial Restructuring -- New York
- David Knight, Private Equity Performance Improvement -- Houston
- Daniel LaMantia, Private Equity Performance Improvement -- Dallas
- Erin Leveton, Public Sector Services -- Washington, D.C.
- Allen Mahr, North American Commercial Restructuring -- New York
- Matthew Merhan, Corporate Performance Improvement -- Houston
- Derek Myers, Tax -- Atlanta
- Rich Niemerg, North American Commercial Restructuring -- Chicago
- Alan Pender, Energy -- Dallas
- Rob Reid, Infrastructure & Capital Projects (A&M INFRA) -- Atlanta
- Jeffrey Richman, Corporate Finance -- New York
- Brian Rudelson, Tax -- Houston
- Joan Russo, Healthcare -- Miami
- Paul Saftig, Global Transaction Advisory Group -- Chicago
- John Sawyer, Valuation -- Seattle
- Daniel Schmeltz, Corporate Performance Improvement -- Houston
- Jigar Shah, Corporate Performance Improvement -- Los Angeles
- Michael Shanahan, Global Disputes and Investigations -- Philadelphia
- Jeff Swerdlow, Tax -- Denver
- Andrew Thung, Healthcare -- New York
- Jeremy Tilsner, Global Disputes and Investigations -- New York
- Andrey Ulyanenko, Tax -- Miami
- Aaron Umberger, Public Sector Services -- Washington, D.C.
- Mariya Verbitski, Global Transaction Advisory Group -- San Francisco
North Asia
- Dee Chung, Restructuring & Turnaround -- Seoul
- Carmen Yeung, Restructuring & Turnaround -- Hong Kong SAR
Southeast Asia & Australia
- John Sanger, Performance Improvement -- Perth
- Kaustav Sen, Performance Improvement -- Singapore
About Alvarez & Marsal
Companies, investors and government entities around the world turn to Alvarez & Marsal (A&M) for leadership, action and results. Privately held since its founding in 1983, A&M is a leading global professional services firm that provides advisory, business performance improvement and turnaround management services. When conventional approaches are not enough to create transformation and drive change, clients seek our deep expertise and ability to deliver practical solutions to their unique problems.
With over 8,500 people across six continents, we deliver tangible results for corporates, boards, private equity firms, law firms and government agencies facing complex challenges. Our senior leaders, and their teams, leverage A&M’s restructuring heritage to help companies act decisively, catapult growth and accelerate results. We are experienced operators, world-class consultants, former regulators and industry authorities with a shared commitment to telling clients what’s really needed for turning change into a strategic business asset, managing risk and unlocking value at every stage of growth.
To learn more, visit: AlvarezandMarsal.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240109034313/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
